CD19 and neoplasm: We and other investigators have demonstrated that, upon Reg-1 knock out (KO), tumor-specific CD19-CAR T or T cell receptor (TCR)-transgenic CD8+ T cells persist longer, express more effector molecules, and have increased oxidative phosphorylation (OXPHOS) compared to unmodified T cells10,11,24,25.